PerkinElmer to Support Expanded Neonatal Screening Program in Saudi Arabia.

King Faisal Specialist Hospital and Research Centre to double screening capacity, expand screening program from one to four disorders

WALTHAM, Mass. -- PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences and Photonics, today announced a multi-year agreement with the King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia, to support its expanded newborn screening program. Under the terms of the agreement, PerkinElmer will provide instrumentation, reagents, software and screening expertise that will help the King Faisal Hospital double its screening capacity by the end of 2008. The contract, to be executed through PerkinElmer's regional distributor, HVD Vertriebs Gmbh, will also expand the hospital's program from screening for one disorder to a total of four disorders.

"We are pleased to partner with King Faisal Specialist Hospital and Research Centre to aid in the expansion of its newborn screening program," said Robert F. Friel, President and Chief Operating Officer, PerkinElmer, Inc. "PerkinElmer is committed to supporting early detection programs worldwide with leading neonatal screening technology designed to identify infants at risk for devastating metabolic disorders, enabling early intervention and treatment to save lives and improve quality of life."

Approximately 800,000 babies are born each year in Saudi Arabia, which has a population of about 27.6 million. The King Faisal Hospital is Saudi Arabia's leading provider of neonatal screening for genetic disorders, which allows for the early identification and treatment of otherwise debilitating or life threatening conditions and has become one of the most widely accepted procedures in preventative pediatrics. Through this expanded initiative with PerkinElmer, the King Faisal Hospital hopes to double its screening rate to 200,000 newborns by the end of 2008, and to 400,000 newborns by the end of 2009.

As part of this agreement, the King Faisal Hospital will use Specimen Gate([R]), PerkinElmer's screening laboratory information management system (LIMS). This software will allow the hospital to implement a comprehensive solution that will electronically track laboratory workflow from sample receipt and preparation, through the analytical steps, to quality control review, reporting and follow-up.

PerkinElmer currently provides the King Faisal Hospital with reagents for screening congenital hypothyroidism (CH), which if left untreated can lead to severe mental retardation. Under the expanded program, which will begin in late 2007, three additional tests will be sourced from PerkinElmer including: congenital adrenal hyperplasia (CAH), a hormonal disorder affecting the adrenal glands; Galactosemia, which if left untreated, can cause poor development or death; and biotinidase deficiency (BIOT), which can lead to seizures, developmental delay, eczema and hearing loss.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.